Click here to receive MS news via e-mail
Helius Medical
Technologies Announces Results from a Case Series of Subjects with Advanced MS
– Helius
Press Releases T Helius Medical Technologi…
Newtown, PA– June 21, 2016 – Helius Medical Technologies, Inc. (TSX:
HSM, HSM.S, OTCQB: HSDT) (“Helius” or the “Company”) is pleased
to announce the results of a case series of individuals with advanced symptoms
of Multiple Sclerosis (MS) treated with PoNS™ Therapy.
This study was performed at TCNL1, University of Wisconsin,
Madison and the data was presented at the 2016, Annual Meeting of the
Consortium of Multiple Sclerosis Centers (CMSC).
Six subjects with advanced MS (Expanded Disability Status Scale (EDSS)2
scores ranging from 6.5 to 7.5) were enrolled in a six-month pilot study.
Subjects were trained in PoNS™ Therapy which combines use of the prototype
PoNS™ device with physical training in balance, gait, movement and postural
stability. Results demonstrated improvements in physical, cognitive and quality
of life parameters. The demanding training regimen also resulted in
significant real life improvements such as re-adopting a walker for community
mobility, decreased fatigue, increased independence with daily activities,
overcoming physical obstacles at home and increased community access.
“Those with greater functional ability at the beginning of the study (EDSS
6.5-7.0) made the most significant gains but all subjects could be qualified as
improved. The intervention shows promise to prolong functional ambulation and independence
with daily activity,” said Principal Investigator Mitch Tyler.
In a separate MS Pilot study, sponsored by Helius (see press release
November 2, 2015), the average EDSS score of the subjects was 4.5, while the
average in this subject pool was 7.0. In applauding the efforts of the
TCNL investigators, Helius CEO Phillippe Deschamps noted, “The patients in this
study represent a much more challenging cohort and received PoNSTM
Therapy for a longer period (6-months vs. 14-weeks), yet compliance remained
high. The outcome is very encouraging”.
1) The TCNL is the Tactile Communications and Neurorehabilitation Laboratory
at the University of Wisconsin, Madison. The PoNS™ was developed at TCNL and
licensed to a Helius subsidiary..
2) EDSS is a measure of MS disease severity where 0=normal and
10=death.
About PoNS™ Therapy
The Portable Neuromodulation Stimulator (PoNS™) is an investigational
non-invasive device designed to deliver neurostimulation through the
tongue. PoNS™ Therapy combines the use of the device with physical
therapy and is currently being evaluated in a multicenter clinical trial for
the treatment of balance disorder for subjects with mild to moderate Traumatic
Brain Injury.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a medical technology company focused on
neurological wellness. Helius seeks to develop, license and acquire
unique and non-invasive platform technologies that amplify the brain’s ability
to heal itself. Helius intends to file for FDA clearance for the PoNS™
device. For more information, please visit www.heliusmedical.com.
The Toronto Securities Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this news
release.
Cautionary Disclaimer Statement:
Certain statements in this news release are not based on historical facts
and constitute forward-looking statements or forward-looking information within
the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and
Canadian securities laws (“forward-looking statements”).
All statements other than statements of historical fact included in this
news release are forward-looking statements that involve risks and
uncertainties. Such forward-looking statements include, among others, statements
regarding ongoing or planned clinical research, expected future development
timelines, regulatory approvals, business initiatives and objectives and use of
proceeds from financings or other business initiatives.
Forward-looking statements are often identified by terms such as “will”,
“may”, “should”, “anticipate”, “expects” and similar expressions.
There can be no assurance that such statements will prove to be accurate and
actual results and future events could differ materially from those anticipated
in such statements. Important factors that could cause actual results to differ
materially from the Company’s expectations include the failure of the Company
to achieve its business objectives and other risks detailed from time to time
in the filings made by the Company with securities regulators.
The reader is cautioned that assumptions used in the preparation of any
forward-looking statements may prove to be incorrect. Events or circumstances
may cause actual results to differ materially from those predicted, as a result
of numerous known and unknown risks, uncertainties, and other factors, many of
which are beyond the control of the Company. The reader is cautioned not to
place undue reliance on any forward-looking statement. Such information,
although considered reasonable by management at the time of preparation, may
prove to be incorrect and actual results may differ materially from those
anticipated. Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement. Risks and uncertainties about
the Company’s business are more fully discussed in the Company’s disclosure
materials, including the short form prospectus filed in connection with the
Offering, its Annual Report on Form 10-K filed with the United States
Securities and Exchange Commission and the Canadian securities regulators and
which can be obtained from either at www.sec.gov
or www.sedar.com.
The forward-looking statements contained in this news release are made as of
the date of this news release and the Company assumes no obligation to update
any forward-looking statement or to update the reasons why actual results could
differ from such statements except to the extent required by law.
# # #
Source link
MS Views and News
Providing educational information, resources and services for those affected by MS